Rickert D E
Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina 27709.
Drug Metab Rev. 1987;18(1):23-53. doi: 10.3109/03602538708998299.
There appear to be two major pathways for the metabolism of nitrobenzene and substituted nitrobenzenes. The first of these is reduction of the nitro group to yield aniline or substituted anilines. For nitrobenzene and perhaps for pentachloronitrobenzene, reduction of the nitro group to the amine is accomplished by bacteria of the gastrointestinal tract. Addition of a second nitro group results in easier reduction of one of the nitro groups on dinitrobenzenes, since they can be reduced under aerobic conditions by hepatic and erythrocyte enzymes. Bacterial reduction of the dinitrobenzenes is probably not quantitatively important in vivo. The second pathway is replacement of a nitro group by glutathione. The relative importance of this pathway compared to nitro group reduction depends upon the compound. It has not been demonstrated to occur for nitrobenzene. It is the major route of metabolism for 1,2-dinitrobenzene but is not an important route for 1,3- or 1,4-dinitrobenzene in hepatocytes. Tetrachloronitrobenzene isomers in which the nitro group is flanked by chlorines and pentachloronitrobenzene undergo nitro group replacement, but 2,3,4,5-tetrachloronitrobenzene does not. The most important pathway for the metabolism of mononitrotoluenes is methyl group oxidation. All quantitatively important metabolites are apparently formed from the nitrobenzyl alcohols. The mono- and dinitrotoluenes are not significantly reduced to isolatable metabolites by mammalian enzymes in vivo; intestinal microflora reduce these compounds after biliary excretion of the nitrobenzyl glucuronides. The little available evidence suggests that this is not the case for trinitrotoluenes. Urinary metabolites retain the methyl group and bear one or two amino groups. This suggests either that mammalian enzymes are capable of reducing the nitro groups of trinitrotoluenes in vivo or that intestinal microflora gain access to unmodified trinitrotoluene. The nitropolycyclic aromatic hydrocarbons are apparently metabolized by both nitro reduction and ring oxidation. There is good evidence, at least for 1-nitropyrene and 6-nitrobenzo[a]pyrene, that nitro reduction occurs in intestinal microflora. the complexities of foreign compound metabolism are well illustrated by the biotransformation of the nitroaromatic compounds. Positional isomers are preferentially metabolized by markedly different pathways. Substitution to different degrees or with different functional groups greatly affects the types of metabolites formed. Yet these compounds also offer opportunities for understanding the mechanisms of foreign compound metabolism.(ABSTRACT TRUNCATED AT 400 WORDS)
硝基苯和取代硝基苯的代谢似乎有两条主要途径。第一条途径是硝基还原生成苯胺或取代苯胺。对于硝基苯以及可能对于五氯硝基苯来说,胃肠道细菌可将硝基还原为胺。在二硝基苯上增加第二个硝基会使其中一个硝基更易被还原,因为它们可在有氧条件下被肝脏和红细胞中的酶还原。二硝基苯的细菌还原在体内可能在数量上并不重要。第二条途径是谷胱甘肽取代硝基。与硝基还原相比,这条途径的相对重要性取决于化合物。尚未证明硝基苯会发生这种情况。它是1,2 - 二硝基苯代谢的主要途径,但在肝细胞中对于1,3 - 二硝基苯或1,4 - 二硝基苯来说并非重要途径。硝基两侧有氯原子的四氯硝基苯异构体和五氯硝基苯会发生硝基取代,但2,3,4,5 - 四氯硝基苯不会。一硝基甲苯代谢的最重要途径是甲基氧化。所有在数量上重要的代谢产物显然都由硝基苄醇形成。一硝基甲苯和二硝基甲苯在体内不会被哺乳动物酶显著还原为可分离的代谢产物;肠道微生物群在硝基苄葡糖苷酸经胆汁排泄后会还原这些化合物。现有少量证据表明三硝基甲苯并非如此。尿液代谢产物保留甲基并带有一个或两个氨基。这表明要么哺乳动物酶能够在体内还原三硝基甲苯的硝基,要么肠道微生物群能够接触到未修饰的三硝基甲苯。硝基多环芳烃显然通过硝基还原和环氧化进行代谢。至少对于1 - 硝基芘和6 - 硝基苯并[a]芘来说,有充分证据表明肠道微生物群中会发生硝基还原。硝基芳香化合物的生物转化很好地说明了外源化合物代谢的复杂性。位置异构体优先通过明显不同的途径进行代谢。不同程度的取代或不同官能团的取代会极大地影响所形成代谢产物的类型。然而这些化合物也为理解外源化合物代谢机制提供了机会。(摘要截选至400字)